AMRX
Amneal Pharmaceuticals Inc. · NASDAQ
- Market cap
- $7.45B
Amneal Pharmaceuticals Inc. (AMRX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for AMRX, including 9 press releases and news items, 3 SEC filings and 1 earnings update. The most recent was published Nov 10, 2026.
AMRX rankings
Financial highlights
Full financials- Revenue, TTM
- $3.20B
- Revenue growth
- +8.9%
- Net income, TTM
- $133.30M
- Net margin
- 4.2%
- Free cash flow, TTM
- $88.19M
- Cash
- $157.40M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks46+500%
2026-05-242026-11-15
Mix2290d
- Other10(45%)
- Insider4(18%)
- SEC Filings4(18%)
- Analyst2(9%)
- Earnings2(9%)
Activity · 52 weeks11056 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRAmneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large EmployersBRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced that it has been named a BioSpace 2027 Best Place to Work, earning the No.1 ranking among large employers in the life sciences industry. The recognition marks the second consecutive year Amneal has been named to BioSpace’s Best Places to Work list, rising from the No.4 ranking among large employers last year. "We are incredibly proud to be recognized as the No.1 Best Place to Work among large employers by BioSpace," said Nikita Shah, Executive Vice President and Chief Human Resources Officer of Amneal. "This recognition belongs to our people and refle
- FDAFDA Approval for FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE issued to IMPAX PHARMSSubmission status for IMPAX PHARMS's drug FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE (SUPPL-4) with active ingredient FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE has changed to 'Approval' on 11/03/2026. Application Category: ANDA, Application Number: 076298, Application Classification: Labeling
- FDAFDA Approval for ISOTRETINOIN issued to AMNEAL PHARMS NYSubmission status for AMNEAL PHARMS NY's drug ISOTRETINOIN (SUPPL-4) with active ingredient ISOTRETINOIN has changed to 'Approval' on 11/03/2026. Application Category: ANDA, Application Number: 216097, Application Classification: Labeling
- FDAFDA Approval for ISOTRETINOIN issued to AMNEAL PHARMS NYSubmission status for AMNEAL PHARMS NY's drug ISOTRETINOIN (SUPPL-2) with active ingredient ISOTRETINOIN has changed to 'Approval' on 11/03/2026. Application Category: ANDA, Application Number: 216097, Application Classification: Labeling
- SECSEC Form 10-Q filed by Amneal Pharmaceuticals Inc.10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
- FDAFDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMSSubmission status for AMNEAL PHARMS's drug MOMETASONE FUROATE (SUPPL-15) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 10/30/2026. Application Category: ANDA, Application Number: 207989, Application Classification: Labeling
- FDAFDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMSSubmission status for AMNEAL PHARMS's drug MOMETASONE FUROATE (SUPPL-11) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 10/30/2026. Application Category: ANDA, Application Number: 207989, Application Classification: Labeling
- FDAFDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMSSubmission status for AMNEAL PHARMS's drug MOMETASONE FUROATE (SUPPL-3) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 10/30/2026. Application Category: ANDA, Application Number: 207989, Application Classification: Labeling
- FDAFDA Approval for CYCLOPHOSPHAMIDE issued to AMNEAL PHARMSSubmission status for AMNEAL PHARMS's drug CYCLOPHOSPHAMIDE (ORIG-1) with active ingredient CYCLOPHOSPHAMIDE has changed to 'Approval' on 11/02/2026. Application Category: ANDA, Application Number: 210890, Application Classification:
- FDAFDA Approval for GUAIFENESIN issued to AMNEAL PHARMSSubmission status for AMNEAL PHARMS's drug GUAIFENESIN (SUPPL-17) with active ingredient GUAIFENESIN has changed to 'Approval' on 11/03/2026. Application Category: ANDA, Application Number: 207342, Application Classification: Labeling
- SECAmneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
- PRAmneal Reports Third Quarter 2026 Financial Results– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) –– Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 –– Updating 2026 Full Year Guidance – BRIDGEWATER, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2026. "Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimi
- SECAmendment: SEC Form 8-K/A filed by Amneal Pharmaceuticals Inc.8-K/A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
- PRAmneal to Report Third Quarter 2026 Results on November 3, 2026BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code is 304152835. A replay of the webcast will be available shortly
- ANALYSTOppenheimer initiated coverage on Amneal Pharmaceuticals with a new price targetOppenheimer initiated coverage of Amneal Pharmaceuticals with a rating of Outperform and set a new price target of $27.00
- INSIDERDirector Buchi J Kevin gifted 20,445 shares (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
- PRAmneal Announces FDA Approval and Launch of Lanreotide Injection- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA. "The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines bus
- INSIDERDirector Buchi J Kevin exercised 20,445 shares at a strike of $14.45, increasing direct ownership by 27% to 95,522 units (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
- ANALYSTLeerink Partners initiated coverage on Amneal Pharmaceuticals with a new price targetLeerink Partners initiated coverage of Amneal Pharmaceuticals with a rating of Outperform and set a new price target of $23.00
- SECSEC Form S-3ASR filed by Amneal Pharmaceuticals Inc.S-3ASR - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
- INSIDERExecutive Vice President Boyer Andrew S gifted 80,000 shares, decreasing direct ownership by 29% to 193,646 units (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
- INSIDERExecutive Vice President Boyer Andrew S gifted 152,426 shares, decreasing direct ownership by 36% to 273,646 units (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
- INSIDERDirector Kiely John sold $882,000 worth of shares (50,000 units at $17.64) and gifted 10,000 shares, decreasing direct ownership by 23% to 200,252 units (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
- INSIDERExecutive Vice President Shah Nikita sold $2,563,517 worth of shares (146,403 units at $17.51), decreasing direct ownership by 37% to 253,390 units (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
- INSIDEREVP, Chief Legal Officer Daly Jason B. sold $3,771,050 worth of shares (216,613 units at $17.41), decreasing direct ownership by 86% to 35,171 units (SEC Form 4)4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
AMRX FAQ
10 questionsWhat does Amneal Pharmaceuticals Inc. do?
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of...What is the latest news on AMRX?
In the last 30 days Quantisnow tracked 13 wire items for AMRX: 9 press releases and news items, 3 SEC filings and 1 earnings update. The most recent was published on November 10, 2026.What is AMRX revenue?
Amneal Pharmaceuticals Inc. (AMRX) reported $3.20B of revenue for the twelve months ended Sep 30, 2026. That is up 8.9% from the year before. Revenue for fiscal 2025 was $3.02B.Is AMRX profitable?
Yes. Amneal Pharmaceuticals Inc. earned $133.30M in net income for the twelve months ended Sep 30, 2026, a net margin of 4.2%.How much cash and debt does AMRX have?
Amneal Pharmaceuticals Inc. reported $157.40M in cash and cash equivalents and $2.94B of debt on its most recent balance sheet in SEC filings.Where does AMRX stock trade?
Amneal Pharmaceuticals Inc. (AMRX) is listed on NASDAQ.What sector and industry is AMRX in?
Amneal Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AMRX?
Across the last 7 analyst actions on Amneal Pharmaceuticals Inc., there were 2 upgrades and 0 downgrades. The most recent action was from Oppenheimer: Outperform with a $27.00 price target on 2026-09-23. Recent price targets range from $9.00 to $27.00.What companies are similar to AMRX?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare AMRX side-by-side with any of them on Quantisnow.How can I track AMRX on Quantisnow?
Quantisnow aggregates Amneal Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMRX to receive live email and push alerts on every new disclosure.